Amid Pandemic, Global Venture Investors See Opportunities in China

Katherine Andersen

Key Takeaways

  • Silicon Valley Bank first established a presence China in 1999.
  • This SVB report is produced in collaboration with SPD Silicon Valley Bank, our joint venture established.
  • We cover the investment trends across China’s healthcare ecosystem and cross-border opportunities for US and EMEA-based companies.

China’s innovation economy is an amazing success story, and Silicon Valley Bank is proud to be part of it — since 1999, when we established our first presence in Shanghai. In 2012, we built on that success when we established SPD Silicon Valley Bank (SSVB), a joint venture with the Shanghai Pudong Development Bank and the first technology and innovation bank of its kind in China.

This dynamic partnership, which now includes branches in Beijing and Shenzhen, has grown to serve Chinese founders and innovation companies with core banking products, including RMB-denominated accounts, while helping promote collaboration and investment by US and EMEA companies in the Chinese innovation economy. In the life science and healthcare space, SVB and SSVB together serve more than 3,500 clients globally, with the shared mission to increase our clients’ probability of success and be the most sought-after partner globally for innovators, enterprises and investors.

Underscoring this commitment, I’m pleased to share this inaugural China healthcare report, produced in collaboration with SSVB. The report highlights China and cross-border trends from SVB’s rich proprietary intelligence, as well as insights from interviews with more than two dozen companies and investors in the US, Shanghai and Beijing. It comes six years after we launched the Healthcare Capital & Connections Summit, a global cross-border healthcare conference in Shanghai, to nurture US, EMEA and China collaborations and partnerships.

While the global COVID-19 pandemic continues to dominate headlines, the US and China — the world’s two largest healthcare markets — are working to solve enormous healthcare challenges. On the global healthcare stage, biopharma is consistently the leading subsector in terms of invested capital. China remains a strong contributor and value driver due to its skilled workforce and growing consumer demand to address the healthcare priorities of its growing middle class and aging population. 

While we’re faced with many uncertainties in 2020, the fundamentals for healthcare and the life sciences remain strong, and the tightknit community that composes our industry is positioned to navigate the path forward – together. Healthcare and technology will continue to converge on a global scale, and with SVB’s global footprint and position at the center of the innovation ecosystem, we’re well prepared to help you succeed. The future of truly disruptive healthcare innovation is here — and it’s global.

Read this next

China's Role in Global Healthcare

Covid-19 has not thwarted private, venture-backed healthcare companies from raising money and closing active deals.
Read report

Global Life Science and Healthcare

We help companies advancing the future of healthcare scale effectively at every stage of growth.
Learn more

china healthcare report

Katherine Andersen
Written by
Katherine Andersen
Katherine serves as Head of Life Science & Healthcare Relationship Banking and sits on the board of SVB's joint venture in China, SPD Silicon Valley Bank.
This material including, without limitation, to the statistical information herein, is provided for informational purposes only. The material is based in part on information from third-party sources that we believe to be reliable but which have not been independently verified by us, and for this reason, we do not represent that the information is accurate or complete. The information should not be viewed as tax, investment, legal or other advice, nor is it to be relied on in making an investment or other decision. You should obtain relevant and specific professional advice before making any investment decision. Nothing relating to the material should be construed as a solicitation, offer or recommendation to acquire or dispose of any investment or to engage in any other transaction.

SPD, SHANGHAI PUDONG DEVELOPMENT BANK, and 浦发银行有限公司 are trademarks, separately and in combination, of Shanghai Pudong Development Bank, Ltd. in China, and are used under license. SPD Silicon Valley Bank is a Sino-U.S. joint-venture bank of Silicon Valley Bank, the California bank subsidiary and commercial banking operation of SVB Financial Group, and Shanghai Pudong Development Bank.

Get monthly startup insights and advice

Insights from SVB Industry Experts

 
SVB experts provide our customers with industry insights, proprietary research and insightful content. Check out these related articles that may be of interest to you.

SVB: Healthcare investing hits new highs

 

A Question of Capital: What first-time founders should consider when raising funding from those who know

 

FX Monthly Outlook: US-China trade risk returns to the fore as the EU discusses stimulus spending

 

Kindred Capital: Driving VC funding in the UK

 

Challenges and Opportunities For Emerging GPs Amid The Covid-19 Crisis

 

FX Monthly Outlook: Markets and the real economy extend their social distancing